Number needed to treat: a descriptor for weighing therapeutic options
- PMID:16174840
- DOI: 10.2146/ajhp040558
Number needed to treat: a descriptor for weighing therapeutic options
Abstract
Purpose: The utility and limitations of the number needed to treat (NNT) are described and compared with those of alternative descriptors of therapeutic yield.
Summary: Pharmacists, physicians, and patients are more likely to launch interventions based on relative measures of therapeutic yield. The NNT is a simple way to express the absolute therapeutic yield of an intervention. It is essential to take baseline risk and length of follow-up into account when calculating and interpreting absolute or relative measures of therapeutic yield. Patients may have difficulty understanding what the NNT tells them about the benefits and harms associated with an intervention, and confidence intervals for the NNT can be difficult to interpret. Relative measures of benefits are advantageous for comparing benefits across populations with different risks. The use of absolute measures to describe therapeutic options leads to more conservative decision-making and is potentially more useful. Among the absolute measures, the absolute risk reduction may be easier to understand than the NNT. These measures are most helpful when the best options are not clear or when patient input is needed. Personal digital assistants and Web-based tools can assist with calculations.
Conclusion: The NNT is a useful measure but is influenced by numerous variables and may not be easily understood by patients.
Similar articles
- Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).Ridker PM, MacFadyen JG, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group.Ridker PM, et al.Circ Cardiovasc Qual Outcomes. 2009 Nov;2(6):616-23. doi: 10.1161/CIRCOUTCOMES.109.848473. Epub 2009 Sep 22.Circ Cardiovasc Qual Outcomes. 2009.PMID:20031900Clinical Trial.
- The effect of alternative summary statistics for communicating risk reduction on decisions about taking statins: a randomized trial.Carling CL, Kristoffersen DT, Montori VM, Herrin J, Schünemann HJ, Treweek S, Akl EA, Oxman AD.Carling CL, et al.PLoS Med. 2009 Aug;6(8):e1000134. doi: 10.1371/journal.pmed.1000134. Epub 2009 Aug 25.PLoS Med. 2009.PMID:19707575Free PMC article.Clinical Trial.
- Evidence-based dermatology: number needed to treat and its relation to other risk measures.Manriquez JJ, Villouta MF, Williams HC.Manriquez JJ, et al.J Am Acad Dermatol. 2007 Apr;56(4):664-71. doi: 10.1016/j.jaad.2006.08.024. Epub 2006 Oct 27.J Am Acad Dermatol. 2007.PMID:17367615Review.
- Communicating the benefits and harms of treatments.Akobeng AK.Akobeng AK.Arch Dis Child. 2008 Aug;93(8):710-3. doi: 10.1136/adc.2008.137083. Epub 2008 May 2.Arch Dis Child. 2008.PMID:18456681Review.
- Absolute risk reduction in total mortality with implantable cardioverter defibrillators: analysis of primary and secondary prevention trial data to aid risk/benefit analysis.Betts TR, Sadarmin PP, Tomlinson DR, Rajappan K, Wong KC, de Bono JP, Bashir Y.Betts TR, et al.Europace. 2013 Jun;15(6):813-9. doi: 10.1093/europace/eus427. Epub 2013 Jan 30.Europace. 2013.PMID:23365069
Cited by
- Epidemiological methods: about time.Kraemer HC.Kraemer HC.Int J Environ Res Public Health. 2010 Jan;7(1):29-45. doi: 10.3390/ijerph7010029. Epub 2009 Dec 31.Int J Environ Res Public Health. 2010.PMID:20195431Free PMC article.
- Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis.Dibben GO, Faulkner J, Oldridge N, Rees K, Thompson DR, Zwisler AD, Taylor RS.Dibben GO, et al.Eur Heart J. 2023 Feb 7;44(6):452-469. doi: 10.1093/eurheartj/ehac747.Eur Heart J. 2023.PMID:36746187Free PMC article.Review.
- Primary Thromboprophylaxis in Ambulatory Pancreatic Cancer Patients Receiving Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Frere C, Crichi B, Bournet B, Canivet C, Abdallah NA, Buscail L, Farge D.Frere C, et al.Cancers (Basel). 2020 Jul 24;12(8):2028. doi: 10.3390/cancers12082028.Cancers (Basel). 2020.PMID:32722064Free PMC article.
- Effectiveness of an internet-delivered intervention for generalized anxiety disorder in routine care: A randomised controlled trial in a student population.Richards D, Timulak L, Rashleigh C, McLoughlin O, Colla A, Joyce C, Doherty G, Sharry J, Duffy D, Anderson-Gibbons M.Richards D, et al.Internet Interv. 2016 Oct 29;6:80-88. doi: 10.1016/j.invent.2016.10.003. eCollection 2016 Nov.Internet Interv. 2016.PMID:30135817Free PMC article.
- Lamivudine 24-month-long prophylaxis is a safe and efficient choice for the prevention of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients with advanced DLBCL undergoing upfront R-CHOP-21.Giordano C, Picardi M, Pugliese N, Vincenzi A, Abagnale DP, De Fazio L, Giannattasio ML, Fatigati C, Ciriello M, Salemme A, Muccioli Casadei G, Vigliar E, Mascolo M, Troncone G, Pane F.Giordano C, et al.Front Oncol. 2023 Feb 15;13:1130899. doi: 10.3389/fonc.2023.1130899. eCollection 2023.Front Oncol. 2023.PMID:36890828Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources